147 research outputs found
Tensor-optimized antisymmetrized molecular dynamics as a successive variational method in nuclear many-body system
We study the tensor-optimized antisymmetrized molecular dynamics (TOAMD) as a
successive variational method in many-body systems with strong interaction for
nuclei. In TOAMD, the correlation functions for the tensor force and the
short-range repulsion and their multiples are operated to the AMD state as the
variational wave function. The total wave function is expressed as the sum of
all the components and the variational space can be increased successively with
the multiple correlation functions to achieve convergence. All the necessary
matrix elements of many-body operators, consisting of the multiple correlation
functions and the Hamiltonian, are expressed analytically using the Gaussian
integral formula. In this paper we show the results of TOAMD with up to the
double products of the correlation functions for the s-shell nuclei, 3H and
4He, using the nucleon-nucleon interaction AV8'. It is found that the energies
and Hamiltonian components of two nuclei converge rapidly with respect to the
multiple of correlation functions. This result indicates the efficiency of
TOAMD for the power series expansion in terms of the tensor and short-range
correlation functions.Comment: 7 pages, 5 figures, added references, corrected typo
Newly-established Chinese hamster-derived cell line for protein production
Please click Additional Files below to see the full abstract
Cooperative contributions of Interferon regulatory factor 1 (IRF1) and IRF8 to interferon-γ-mediated cytotoxic effects on oligodendroglial progenitor cells
<p>Abstract</p> <p>Background</p> <p>Administration of exogenous interferon-γ (IFNγ) aggravates the symptoms of multiple sclerosis (MS), whereas interferon-β (IFNβ) is used for treatment of MS patients. We previously demonstrated that IFNγ induces apoptosis of oligodendroglial progenitor cells (OPCs), suggesting that IFNγ is more toxic to OPCs than IFNβ. Thus we hypothesized that a difference in expression profiles between IFNγ-inducible and IFNβ-inducible genes in OPCs would predict the genes responsible for IFNγ-mediated cytotoxic effects on OPCs. We have tested this hypothesis particularly focusing on the interferon regulatory factors (IRFs) well-known transcription factors up-regulated by IFNs.</p> <p>Methods</p> <p>Highly pure primary rat OPC cultures were treated with IFNγ and IFNβ. Cell death and proliferation were assessed by MTT reduction, caspse-3-like proteinase activity, Annexin-V binding, mitochondrial membrane potential, and BrdU-incorporation. Induction of all nine IRFs was comprehensively compared by quantitative PCR between IFNγ-treated and IFNβ-treated OPCs. IRFs more strongly induced by IFNγ than by IFNβ were selected, and tested for their ability to induce OPC apoptosis by overexpression and by inhibition by dominant-negative proteins or small interference RNA either in the presence or absence of IFNγ.</p> <p>Results</p> <p>Unlike IFNγ, IFNβ did not induce apoptosis of OPCs. Among nine IRFs, IRF1 and IRF8 were preferentially up-regulated by IFNγ. In contrast, IRF7 was more robustly induced by IFNβ than by IFNγ. Overexpressed IRF1 elicited apoptosis of OPCs, and a dominant negative IRF1 protein partially protected OPCs from IFNγ-induced apoptosis, indicating a substantial contribution of IRF1 to IFNγ-induced OPC apoptosis. On the other hand, overexpression of IRF8 itself had only marginal proapoptotic effects. However, overexpressed IRF8 enhanced the IFNγ-induced cytotoxicity and the proapoptotic effect of overexpressed IRF1, and down-regulation of IRF8 by siRNA partially but significantly reduced preapoptotic cells after treatment with IFNγ, suggesting that IRF8 cooperatively enhances IFNγ-induced OPC apoptosis.</p> <p>Conclusions</p> <p>This study has identified that IRF1 and IRF8 mediate IFNγ-signaling leading to OPC apoptosis. Therapies targeting at these transcription factors and their target genes could reduce IFNγ-induced OPC loss and thereby enhance remyelination in MS patients.</p
- …